Tom Wessel, M.D., Ph.D. is a board-certified neurologist with more than 25 years of drug development experience, including as medical lead for three CNS products approved in the United States: Razadyne®, Lunesta® and Ampyra®.
Previously, Dr. Wessel served as Executive Vice President, Research and Development at Relmada Therapeutics where he lead all clinical development and regulatory activities. Prior to Relmada he served as Chief Medical Officer at Asceneuron, Chief Medical Officer at Flex Pharma, Chief Medical Officer at Acorda Therapeutics, Senior Vice President of Clinical Research at Sepracor and worked on several CNS projects at Janssen Pharmaceutica in Europe and the United States.
Dr. Wessel received his M.D. from the Ludwig-Maximilians-University in Munich and his Ph.D. in experimental neurobiology at the Max- Planck-Institute for Psychiatry in Martinsried, Germany. He completed his residency in neurology at New York Hospital and Memorial Sloan-Kettering Cancer Center (Cornell University Medical Center) where he remained on the faculty for several years as an Instructor and Assistant Professor before joining the industry.